Argus raised the firm’s price target on Boston Scientific to $55 from $50 and keeps a Buy rating on the shares. As the pandemic has receded and elective procedural volumes have recovered, Boston Scientific has seen strong results in all business segments, and looking ahead, the company should continue to benefit from its diverse product portfolio and commitment to innovation, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific price target raised to $53 from $48 at Needham
- Boston Scientific price target raised to $52 from $50 at Stifel
- Piper remains bullish on Boston Scientific, says guidance likely conservative
- Boston Scientific sees FY23 adjusted EPS $1.86-$1.93, consensus $1.93
- Boston Scientific sees Q1 adjusted EPS 42c-44c, consensus 44c